Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on BI 409306 PK in Healthy Volunteers
NCT02248259Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of osoresnontrine in schizophrenia and Alzheimer's disease (AD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity at 72 hours and Maximum measured concentration of the analyte in plasma at 72 hours. Started Oct 2014; status: completed.
02
Drugs
osoresnontrine
03
Conditions
schizophreniaAlzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02248259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02248259.